Publications
2 shownAdjuvant Olaparib for Patients with <i>BRCA1</i> - or <i>BRCA2</i> -Mutated Breast Cancer
Among patients with high-risk, HER2-negative early breast cancer and germline <i>BRCA1</i> or <i>BRCA2</i> pathogenic or likely pathogenic variants, adjuvant olaparib after comp...
Frequent Co-Authors
Researcher Info
- h-index
- 2
- Publications
- 2
- Citations
- 3,416
- Institution
- Dana-Farber Cancer Institute
External Links
Identifiers
- ORCID
- 0000-0001-9449-3982
Impact Metrics
h-index
2
h-index: Number of publications with at least h citations each.